Novo Nordisk A/ S stock (DK0060534915): weight-loss drugs keep growth story in focus

Novo Nordisk A/S remains in the spotlight as demand for its GLP?1 weight-loss and diabetes drugs continues to drive sales and market value, keeping the Danish pharma group relevant for US investors through its New York listing and exposure to the obesity treatment boom.

Novo Nordisk A/S continues to attract strong investor attention as its GLP?1-based diabetes and obesity treatments, including Ozempic and Wegovy, reshape the global market for metabolic disease therapies, according to company updates and recent financial disclosures from early 2025 and 2024.

As of: 05/18/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Novo Nordisk
• Sector/industry: Pharmaceuticals, diabetes and obesity care
• Headquarters/country: Bagsværd, Denmark
• Core markets: Diabetes, obesity and rare disease treatments worldwide
• Key revenue drivers: GLP?1 drugs for type 2 diabetes and obesity
• Home exchange/listing venue: Nasdaq Copenhagen; US listing via NYSE (NVO)
• Trading currency: Danish krone in Copenhagen; US dollars on NYSE

Novo Nordisk A/S: core business model

Novo Nordisk A/S is a global healthcare company focused primarily on diabetes care, obesity treatments and therapies for rare endocrine and blood disorders. The group has built its business on insulin and, in recent years, on GLP?1 analogs, which help regulate blood sugar and appetite, positioning the company as a leader in chronic metabolic disease management.

The company reports that diabetes care remains its largest franchise, with products including basal insulin, rapid-acting insulin and GLP?1-based therapies designed for type 2 diabetes, according to its 2024 annual reporting and investor materials published in early 2025 from Bagsværd, Denmark, where the company is headquartered, as noted in corporate documents.

Over time, Novo Nordisk A/S has expanded beyond diabetes into obesity care, leveraging similar GLP?1 mechanisms to target weight management in patients with high body mass index and related comorbidities, a strategic shift that has significantly altered its revenue mix and growth outlook in the last few years, based on company commentary and presentations.

Main revenue and product drivers for Novo Nordisk A/S

The key revenue drivers for Novo Nordisk A/S now include GLP?1 drugs prescribed for type 2 diabetes and chronic weight management, with brand families that encompass products marketed globally for lowering blood sugar, reducing cardiovascular risk and supporting clinically meaningful weight loss, as described in company product overviews and recent earnings communications.

Insulin therapies continue to represent an important part of the business, but their relative share of total sales has declined as newer GLP?1 products gain traction; this shift is reflected in revenue breakdowns presented in the company’s 2024 annual report, where management highlighted faster growth in newer generation therapies compared to more mature insulin franchises.

Novo Nordisk A/S also maintains a smaller but strategically important portfolio in rare disease, including therapies for hemophilia and growth disorders, which provide diversification beyond metabolic disease and can support pricing power due to the specialized nature of these treatments, according to the group’s product pipeline and rare disease segment descriptions in its latest published materials.

Conclusion

Novo Nordisk A/S has evolved from a primarily insulin-focused company into a leading player in GLP?1-based diabetes and obesity treatments, which now shape its growth profile and investor perception. For US investors, the group’s New York listing and strong exposure to obesity and diabetes markets provide a direct link to trends in metabolic health. At the same time, factors such as competition in weight-loss drugs, regulatory developments and capacity expansion plans remain important variables for the company’s long-term earnings path and stock volatility.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.